Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Vir Biotechnology Inc V.VIR


Primary Symbol: VIR

Healthcare Biotechnology
Vir Biotechnology, Inc. is an immunology company, which is focused on combining cutting-edge technologies to treat and prevent serious infectious diseases and other serious conditions. The Company's clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). It also has several preclinical candidates in its pipeline including those targeting influenza A and B, COVID-19, respiratory syncytial virus and human metapneumovirus (RSV and MPV), and human papillomavirus (HPV). The Company's pipeline includes VIR-1949, VIR-7229, VIR-2981, VIR-8190, and HIV Cure. It also engaged in developing tobevibart, a monoclonal antibody also known as VIR-3434, and Elebsiran, an siRNA also known as VIR-2218, for the treatment and suppression of chronic HDV. Its Elebsiran is an investigational HBV-targeted siRNA that reduces HBsAg, a protein which is required for the HDV viral life cycle.


NDAQ:VIR - Post by User

Vir Biotechnology Inc > Is it time to buy Experion now?
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(3)
•••
Post by mrwhiteduckon Oct 23, 2019 11:16am
80 Views
Post# 30258910

Is it time to buy Experion now?

Is it time to buy Experion now?TORONTO, Oct. 22, 2019 (GLOBE NEWSWIRE) -- today revealed a sneak peek at the shortlisted Canadian Cannabis Awards (CCAs) nominees in six key categories which represent the spirit and ingenuity of the first year of legalization in Canada: Entrepreneur of the Year, Womxn in Weed—Trailblazer, Top Budtender, Top Master Grower, Top Retail Store—Single Location, and Startup of the Year. Winners in a total of 32 categories will be announced at the CCAs black-tie gala on November 8, 2019 at the Fairmont Royal York hotel in downtown Toronto.

Top Master Grower
The backbone of the industry, these individuals excel in all phases of the growing process, setting themselves apart by demonstrating superb management characteristics, commitment to quality product and a passion for the industry.

  • Kevin Anderson, Broken Coast Cannabis Ltd.
  • John Barnet, Aurora Cannabis
  • Leo Benne, Zenabis Global Inc.
  • Melanie Carruthers, 7ACRES
  • Liam McKenzie, Experion Biotechnologies Inc.
 One of the top FIVE  not bad,this quiet company is sneeking by only to come out soon as the great company it is.
keep yuor eyes on this one.
Is it time to buy now.?
I this so
i am 
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities